Skip to main content

$0 Cost-Share for Monkeypox Diagnosis, Testing and Vaccine Administration

September 08, 2022

To: All Providers

Contracts Affected: Commercial

Following a recent New York State (NYS) Executive Order, we’re waiving copays, coinsurances and deductibles for the diagnosis and testing of Monkeypox1 as well as vaccine administration for your Highmark Blue Shield of Northeastern New York (Highmark BSNENY) fully-insured Commercial patients.

Beginning August 28, 2022 through September 27 (or the end of the NYS Public Health Emergency) your Highmark BSNENY fully-insured Commercial patients will not have to pay a cost-share for:

  • Monkeypox vaccine administration from in- and out-of-network providers
  • Diagnostic testing from an in-network provider or laboratory (HSA-qualified plans excluded)
  • Office, urgent care, emergency department, outpatient OR telehealth visits with an in-network provider to diagnose Monkeypox2 (HSA-qualified plans excluded)

Your office should not collect a cost-share for these patients.

For additional information on Monkeypox, please visit the NYS Department of Health and CDC websites below.

Recent Articles

  • 2023 Medicare Advantage Drug Formulary and Pharmacy Prior Authorization Changes
    Beginning January 1, 2023, some of your Highmark Blue Shield of Northeastern New York (Highmark BSNENY) Medicare Advantage patients may be affected by changes to Highmark’s pharmacy drug formulary. In early December, please be on the lookout for letters detailing select formulary changes affecting your Medicare Advantage patients. Medication-related prior authorization requests will be submitted to and reviewed by our Utilization Management (UM) team. In this article, you can review 2023 formulary updates along with information about the Medicare Advantage pharmacy prior authorization review process as all Medicare Advantage members move onto Highmark’s system.
  • Enhancements to NaviNet Prior Authorization Experience
    We will begin rolling out enhancements to our utilization management (UM) tool through NaviNet on January 1, 2023. These enhancements are intended to streamline your experience by enabling faster reviews and greater transparency around the status of your authorization requests. Here, you can find tips for submitting NaviNet authorization requests on the new platform.
  • Prior Authorization Changes Postponed for Musculoskeletal Procedures and Pain Management, Molecular and Genomic Testing, and Radiation Oncology
    We are postponing the authorization requirement changes for some musculoskeletal (MSK) procedures and interventional pain management, molecular and genomic testing, and radiation oncology services that we announced last month. The requirement updates, which will be managed by eviCore, will not take effect until late Q1 or early Q2. Webinars will be scheduled to orient providers to the eviCore programs before they take effect.
  • Reimbursement Reduction for Cassette-Based X-Ray Imaging
    Effective February 27, 2023, the reduction applied to the reimbursement for X-ray services using computerized radiography cassette-based imaging (FY modifier) is increasing from 7% to 10% (3% additional reduction) for your Highmark Blue Shield of Northeastern New York commercial and Medicare Advantage patients. In this article, you can access the updated reimbursement policy.
  • Two Injectables to Require Prior Authorization Beginning March 1
    On March 1, 2023, two injectable drugs will require prior authorization. Here, you can view the codes as well as additional information about prior authorizations.

Working with Us

Additional Resources

We want to hear from you! Have a topic request for the next Blue Bulletin? Email us

Stay in Touch! Sign up to receive emails for provider news and information